Nutriband Inc. (NASDAQ: NTRB) has achieved a significant milestone by being added to four Russell indexes as part of the 2025 reconstitution. The company is now part of the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes. This inclusion is a testament to the growing market recognition of Nutriband's innovative AVERSA technology, particularly its AVERSA Fentanyl patch, which is designed to prevent the abuse, misuse, and accidental exposure of drugs with high abuse potential.
Gareth Sheridan, CEO of Nutriband, highlighted the importance of this achievement, noting it reflects the momentum behind the company's AVERSA pipeline. The AVERSA Fentanyl patch, a key product in Nutriband's portfolio, has projected peak annual U.S. sales between $80 million and $200 million, indicating significant commercial potential. The Russell indexes, maintained by FTSE Russell, are a benchmark for approximately $10.6 trillion in assets, making Nutriband's inclusion a notable event for investors and the pharmaceutical industry alike.
The addition of Nutriband to these indexes not only elevates the company's profile among investment managers and institutions but also underscores the importance of developing abuse-deterrent technologies in the fight against the opioid crisis. With the AVERSA technology's ability to be incorporated into any transdermal patch, Nutriband is at the forefront of creating safer pharmaceutical options, potentially impacting millions of lives by reducing drug abuse and accidental exposures.
For more details on Nutriband's inclusion in the Russell indexes and its AVERSA technology, visit https://ibn.fm/wa35e.
